506 related articles for article (PubMed ID: 22503210)
1. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
2. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
3. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
4. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
[TBL] [Abstract][Full Text] [Related]
5. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
[TBL] [Abstract][Full Text] [Related]
6. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.
Iwamura K; Kato T; Miyahara Y; Naota H; Mineno J; Ikeda H; Shiku H
Gene Ther; 2012 Oct; 19(10):959-66. PubMed ID: 22113316
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis.
Gary R; Voelkl S; Palmisano R; Ullrich E; Bosch JJ; Mackensen A
J Immunol; 2012 Jan; 188(2):744-52. PubMed ID: 22174448
[TBL] [Abstract][Full Text] [Related]
8. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.
Shi B; Du X; Wang Q; Chen Y; Zhang X
Metabolism; 2013 Jun; 62(6):778-85. PubMed ID: 23398844
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transfected with PD-L1 recombinant adenovirus induces T cell suppression and long-term acceptance of allograft transplantation.
Peng W; Ran B; Ma Y; Huang X; Chang Q; Wang X
Cell Immunol; 2011; 271(1):73-7. PubMed ID: 21855860
[TBL] [Abstract][Full Text] [Related]
11. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
12. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis.
Reynolds J; Sando GS; Marsh OB; Salama AD; Evans DJ; Cook HT; Pusey CD
Nephrol Dial Transplant; 2012 Apr; 27(4):1343-50. PubMed ID: 21965585
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
16. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.
Tang ZS; Hao YH; Zhang EJ; Xu CL; Zhou Y; Zheng X; Yang DL
Mol Med Rep; 2016 Aug; 14(2):1107-16. PubMed ID: 27314219
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Kozako T; Yoshimitsu M; Fujiwara H; Masamoto I; Horai S; White Y; Akimoto M; Suzuki S; Matsushita K; Uozumi K; Tei C; Arima N
Leukemia; 2009 Feb; 23(2):375-82. PubMed ID: 18830259
[TBL] [Abstract][Full Text] [Related]
18. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells.
Gu YZ; Xue Q; Chen YJ; Yu GH; Qing MD; Shen Y; Wang MY; Shi Q; Zhang XG
Hum Immunol; 2013 Mar; 74(3):267-76. PubMed ID: 23261407
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
Trautmann L; Janbazian L; Chomont N; Said EA; Gimmig S; Bessette B; Boulassel MR; Delwart E; Sepulveda H; Balderas RS; Routy JP; Haddad EK; Sekaly RP
Nat Med; 2006 Oct; 12(10):1198-202. PubMed ID: 16917489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
